It is a highly heterogeneous tumor that is clinically classified into four distinct subtypes 2, based on the expression patterns of immunohistochemical markers, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and KI-67. The gene discussed is ERBB2; the disease is neoplasm.